**MINUTES**

**CPIC CONFERENCE CALL**

DATE: July 2, 2020

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Guidelines in progress | Guideline updates in progress:   * *CYP2C9,HLA-B/*phenytoin: Accepted for publication * *CYP2D6*, *OPRM1*, *COMT*/opioids: Drafting manuscript * *CYP2C19/*clopidogrel: Evidence review underway * *G6PD*: Authorship plan underway, starting evidence review * *SLCO1B1*/statins: Authorship plan underway   New guidelines in progress:   * *CYP2C19/*PPIs: Received reviewer comments and re-submitted * *mtRNR1*/aminoglycosides: Evidence review underway | Guideline preparation will continue and Kelly will continue to follow-up. |
| Retiring guidelines | Considering retiring the *IFNL3*/peg-interferon-alpha CPIC guideline. Drug now rarely used, and gene not widely tested due to new drug availability, so not necessarily worth CPIC time/resources compared to other gene/drug pairs; several members indicated during the call that testing is already very rare for this gene. Members pointed out that we will need to investigate further as to the international use of this gene/drug pair. Need to formalize criteria and process for retiring guidelines. Retired guidelines would remain on the CPIC website, but there would be a note that there will not be any further updates. | All: Please email Kelly ([kelly.caudle@stjude.org](mailto:kelly.caudle@stjude.org)) if you have information that would inform whether or not to retire the *IFNL3*/peg-interferon-alpha guideline. |
| Updates to the CPIC gene/drug list | CPIC gene/drug list is reviewed on an ongoing basis CPIC levels are not definitive until a guideline author group systematically reviews the evidence and are therefore subject to change. A major review is ongoing by CPIC staff, addressing the use of hybrid assignments (e.g. A/B or B/C), changing drug classes to specific individual drugs, and other updates based on member input and reviews. Before substantial changes to the gene/drug list are posted publicly, CPIC members will have a chance to review and provide feedback. | All: Please email Kelly ([kelly.caudle@stjude.org](mailto:kelly.caudle@stjude.org)) if you have feedback on the assignment of CPIC levels to gene/drug pairs. |
| PharmVar update | Andrea Gaedigk provided an update on PharmVar. Content has been reorganized to be more user-friendly. API services are now available. Gene documents available, including change logs and structural information. Core allele definitions are provided, with suballeles listed underneath. Comparative Allele ViewEr (CAVE) allows users to visualize and compare haplotypes, including which SNPs are functional and/or unique for selected haplotypes. First PharmVar GeneFocus paper was published in January 2020 on *CYP2D6*. The next one on *CYP2C19* has been e-E-published (32602114, available through the PharmVar resources page). The CYP2C19\*1.001 suballele was revised to \*38, and the \*1 core allele definition updated. The new \*38 allele matches the RefSeq,and does not have any SNPs in its core allele definition. New PharmVar genes page distinguishes between ‘PharmVar Genes’ and ‘Legacy Genes’. The latest gene to be added is *DPYD*, which has a new page format. Working to standardize pharmacogene variation annotations. Slides will be provided with the minutes. |  |
| PGx and use of codeine-containing analgesics in children under 12 y/o-comments requested by FDA | In December 2017, CPIC led the development of a Citizen Petition to amend the April 2017 FDA contraindication of codeine use in children < 12 years old in patients who are known to be CYP2D6 NMs or IMs and who are not post-adenotonsillectomy. FDA is looking for feedback by 8/28/20 on this issue to inform their final decision:  [https://www.federalregister.gov/documents/2020/06/29/2020-13974/use-of-codeine-containing-analgesics-in-children-under-12-years-of-age-subsequent-to-cyp2d6-genetic](https://nam03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2020%2F06%2F29%2F2020-13974%2Fuse-of-codeine-containing-analgesics-in-children-under-12-years-of-age-subsequent-to-cyp2d6-genetic&data=01%7C01%7Croseann.gammal%40stjude.org%7Cff9b63b632f74fba654808d81dc9c005%7C22340fa892264871b677d3b3e377af72%7C0&sdata=CE9R1tYRYjlXSIu%2F7HL3qslRjuxuGdR3i2NGLAVAy00%3D&reserved=0) | All: Please share the link with clinicians who are involved with treating pain in children < 12 years old so that they can provide comment to the FDA. |